Skip to main content

Articles By Jack Cush, MD

kneepain3.jpg (keep)

High Fiber Intake May Decrease Osteoarthritis Knee Pain

  Dai, Felson and colleagues report in Annals of Rheumatic Disease that high dietary fiber lowers the risk of symptomatic osteoathritis (SxOA), but the radiographic benefits remain unclear. (Citation source http://buff.ly/2rHv9yd)

Read Article
WIR.large_.jpg (keep)

The RheumNow Week in Review - 26 May 2017

Dr. Jack Cush Reviews highlights from the past week on RheumNow.com:

Read Article
Sausage061.jpg

Ixekizumab Effective in TNF Failure Psoriatic Arthritis - SPIRIT-P2 Trial

Ixekizumab (Taltz) is currently approved for use in plaque psoriasis and is being developed for use in psoriatic arthritis (PsA). New results show IXE to be highly effective at skin and joint outcomes in PsA patients who have failed a TNF inhibitor (TNFi).

Read Article
fever2.jpg

NLRP3 Activation in Still's Disease

Adult-onset Still disease (AOSD) is usually regarded as an autoinflammatory disease, largely because of its symptomatology and responsiveness to IL-1 inhibition.

Read Article
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis

The NEJM reports success when using mepolizumab (anti-IL-5 monoclonal antibody) in a 52 week study of patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Read Article
FDA%20approved.jpg (keep)

Actemra - First FDA Approved Drug for Giant Cell Arteritis

The FDA has approved subcutaneous tocilizumab for use in Giant Cell Arteritis based on the phase III GiACTA study that demonstrated that TCZ with steroids was superior to steroid therapy alone.

Read Article
FDA%20approved2.jpg

IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis

The FDA has approved sarilumab (Kevzara), a new IL-6 inhibitor co-developed by Regeneron and Sanofi's, for use in adults with moderate to severe rheumatoid arthritis (RA).

Read Article
bone%20dense.jpg (keep)

Anti-Sclerostin Drug Hampered by Heart Problems

Reuters reports that FDA approval of romosozumab (brand name Evenity) may be held up because of higher rates of cardiac events seen in a late-stage clinical trial.

Read Article
WIR.large_.jpg (keep)

The RheumNow Week in Review – 17 May 2017

Dr. Jack Cush reviews highlights and updates from the past week on RheumNow.com:

Read Article
CTRL_0.jpg

My Approach to Difficult RA

Patients are labeled as having “difficult RA" when: 1) we are frustrated, 2) it's too late, 3) we've run out of options or 4) the relationship is failing. We see them, but don’t quite know what to do with them.

Read Article
×